Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anidulafungin to replace caspofungin in the treatment of fungal infections in cancer patients.

Trial Profile

Anidulafungin to replace caspofungin in the treatment of fungal infections in cancer patients.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Nov 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anidulafungin (Primary)
  • Indications Candidaemia; Candidiasis; Systemic mycoses
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
  • 07 Sep 2015 New trial record
  • 25 Aug 2015 Results published in the Journal of Antimicrobial Chemotherapy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top